Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Neurology

Safety, Tolerability, and Efficacy of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Phase 3, Multicenter, 24-week, Open-label Study (P10-15.010)

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJohn RothrockUNUmer NajibJAJessica Ailani

Discussion

Loading...

Member takes

Overview

Phase 3 trial evaluates safety and efficacy of atogepant plus onabotulinumtoxinA for chronic migraine prevention, indicating potential benefits.

Key Points

  • The research aims to assess the safety, tolerability, and efficacy of atogepant when added to onabotulinumtoxinA for chronic migraine prevention.
  • Phase 3, multicenter, open-label trial
  • Participants received atogepant alongside onabotulinumtoxinA
  • Trial duration was 24 weeks
  • Results demonstrate improved efficacy in chronic migraine prevention with the combination treatment
  • Findings suggest increased tolerability and safety with atogepant added to onabotulinumtoxinA

Cite This Study

Rothrock et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf36efaef96ed7f055e2fhttps://doi.org/10.1212/wnl.0000000000215534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study2026
  2. 2Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study)2025
  3. 3Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial2024 · 36 citations
  4. 4Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials2024 · 10 citations
  5. 5Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2026